- Home
- SD vs PVLA Comparison
SD vs PVLA Comparison
Compare SD & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SD
- PVLA
- Stock Information
- Founded
- SD 2006
- PVLA 2015
- Country
- SD United States
- PVLA United States
- Employees
- SD 104
- PVLA N/A
- Industry
- SD Oil & Gas Production
- PVLA Biotechnology: Pharmaceutical Preparations
- Sector
- SD Energy
- PVLA Health Care
- Exchange
- SD Nasdaq
- PVLA Nasdaq
- Market Cap
- SD 351.0M
- PVLA 308.2M
- IPO Year
- SD 2007
- PVLA N/A
- Fundamental
- Price
- SD $9.62
- PVLA $24.36
- Analyst Decision
- SD
- PVLA Strong Buy
- Analyst Count
- SD 0
- PVLA 7
- Target Price
- SD N/A
- PVLA $44.43
- AVG Volume (30 Days)
- SD 395.1K
- PVLA 97.9K
- Earning Date
- SD 05-06-2025
- PVLA 05-15-2025
- Dividend Yield
- SD 4.62%
- PVLA N/A
- EPS Growth
- SD 3.05
- PVLA N/A
- EPS
- SD 1.69
- PVLA N/A
- Revenue
- SD $125,290,000.00
- PVLA N/A
- Revenue This Year
- SD $37.50
- PVLA N/A
- Revenue Next Year
- SD $5.17
- PVLA N/A
- P/E Ratio
- SD $5.69
- PVLA N/A
- Revenue Growth
- SD N/A
- PVLA N/A
- 52 Week Low
- SD $8.81
- PVLA $6.20
- 52 Week High
- SD $14.85
- PVLA $29.27
- Technical
- Relative Strength Index (RSI)
- SD 40.02
- PVLA N/A
- Support Level
- SD $9.14
- PVLA N/A
- Resistance Level
- SD $9.77
- PVLA N/A
- Average True Range (ATR)
- SD 0.51
- PVLA 0.00
- MACD
- SD -0.07
- PVLA 0.00
- Stochastic Oscillator
- SD 29.24
- PVLA 0.00
About SD SandRidge Energy Inc.
SandRidge Energy Inc is a United States-based oil and natural gas company. It is engaged in the exploration, development, and production of crude oil, natural gas, and Natural gas liquids. Business activities of the group include Exploration and Production, Drilling and Oil Field Services, and Midstream Gas Services. Its primary areas of operation are the Mid-Continent in Oklahoma and Kansas.
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. It is developing a broad pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases. Palvella's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations (microcystic LMs) and cutaneous venous malformations.